Condition: Hematologic Malignancy · Haplo-identical Stem Cell Transplantation · Sponsor: University Hospital, Geneva
To assess safety of prophylactic escaladed dose of T naïve depleted (CD45RA depleted donor lymphocyte infusion, in patients with malignant hemopathie who received an allogeneic stem cell transplant from an haplo-identical donor, after a reduced intensity conditionning regiment.
This description comes directly from the study's public registry record.
Anne-Claire Mamez · +41786656487 · anne-claire.mamez@hcuge.ch
Always discuss trial participation with your own doctor first.
| HUG | Geneva, Canton of Geneva, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05066412